

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

FORESIGHT DIAGNOSTICS INC.,
Petitioner,

v.

PERSONALIS, INC.,
Patent Owner.

Case No. IPR2023-00317
U.S. Patent No. 11,408,033

PETITIONER'S UPDATED EXHIBIT LIST

Mail Stop: PATENT BOARD
Patent Trial and Appeal Board
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

<u>PETITIONER’S UPDATED EXHIBIT LIST</u>	
EX1001	U.S. Patent No. 11,408,033 issued to Bartha <i>et al.</i>
EX1002	Rebecca J. Leary <i>et al.</i> , “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing,” <i>Science Translational Medicine</i> (2010) (Leary)
EX1003	Stephen R. Quake <i>et al.</i> , WO 2011/057061 (Quake)
EX1004	Matthew W. Anderson & Iris Schrijver, “Next Generation DNA Sequencing and the Future of Genomic Medicine,” <i>Genes</i> (2010) (Anderson)
EX1005	Andreas Gnirke <i>et al.</i> , “Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing,” <i>Nature Biotechnology</i> (2009) (Gnirke)
EX1006	Florian Mertes <i>et al.</i> , “Targeted enrichment of genomic DNA regions for next-generation sequencing, Briefings in Functional Genomics,” <i>Briefings in Functional Genomics</i> (2011) (Mertes)
EX1007	Lira Mamanova <i>et al.</i> , “Target-enrichment strategies for next-generation sequencing,” <i>Nature</i> (2010) (Mamanova)
EX1008	K.C. Allen Chan <i>et al.</i> , “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing,” <i>Clinical Chemistry</i> (2013) (Chan)
EX1009	Reserved
EX1010	<i>Personalis v. Foresight</i> , First Amended Complaint, D. Colo., Case No. 1:22-v-01913, Dkt. 9, filed August, 17, 2022 (“FAC”)
EX1011	Reserved
EX1012	Timothy J. Ley <i>et al.</i> , “DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome,” <i>Nature</i> (2008) (Ley)

<u>PETITIONER’S UPDATED EXHIBIT LIST</u>	
EX1013	Jay Shendure and Hanlee Ji, “Next-generation DNA sequencing,” <i>Nature Biotechnology</i> (2008) (<i>Shendure</i>)
EX1014	Jeffrey S. Ross and Maureen Cronin, “Whole Cancer Genome Sequencing by Next-Generation Methods,” <i>American Journal of Clinical Pathology</i> (2011) (<i>Ross</i>)
EX1015	David J. McBride, et al., “Use of Cancer-Specific Genomic Rearrangements to Quantify Disease Burden in Plasma from Patients with Solid Tumors,” <i>Genes, Chromosomes & Cancer</i> (2010) (<i>McBride</i>)
EX1016	David M. Kurtz, et al., “Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA,” <i>Nature Biotechnology</i> (2021) (<i>Kurtz</i>) (EXJ to FAC)
EX1017	Dennis Lo, “Cancer Genome Scanning in Plasma, Clinical Chemistry Journal,” Jan. 3, 2013 https://www.aacc.org/science-and-research/clinical-chemistry/clinical-chemistry-podcasts/2013/cancer-genome-scanning-in-plasma-detection-of-tumor-associated-copy-number-aberrations
EX1018	Reserved
EX1019	https://www.genome.gov/about-genomics/fact-sheets/DNA-Sequencing-Costs-Data
EX1020	Declaration of John Quackenbush, Ph.D.
EX1021	Declaration of Ingrid Hsieh-Yee, Ph.D.
EX1022	Caroline Arbanas, “Wilson leads quest to reveal the genome's secrets,” The Source, Washington University St. Louis, April 16, 2008 https://source.wustl.edu/2008/04/wilson-leads-quest-to-reveal-the-genome-secrets/

<u>PETITIONER’S UPDATED EXHIBIT LIST</u>	
EX1023	<i>Curriculum Vitae</i> of John Quackenbush, Ph.D.
EX1024	https://www.garvan.org.au/research/kinghorn-centre-for-clinical-genomics/learn-about-genomics/for-gp/genetics-refresher-1/types-of-variants
EX1025	Reserved
EX1026	Leary Supplemental Information
EX1027	Hugo Lam, et al., “Performance comparison of whole-genome sequencing platforms,” <i>Nature Biotechnology</i> (2012) (Lam)
EX1028	Illumina, Technical Note: Sequencing
EX1029	Illumina, Specification Sheet: Illumina Sequencing
EX1030	Tim Forshew, et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” <i>Science Translational Medicine</i> (2012) (Forshew)
EX1031	Matthew Meyerson, et. al., “Advances in understanding cancer genomes through second-generation sequencing,” <i>Nature Reviews</i> (2010) (Meyerson)
EX1032	Forshew Supplemental Information
EX1033	Nikhil Wagle et al., “High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing,” <i>Cancer Discovery</i> (2012) (Wagle)
EX1034	Andreas Untergasser <i>et al.</i> , “Primer3—new capabilities and interfaces,” <i>Nucleic Acids Res.</i> (2012) (Untergasser)
EX1035	Simon Forbes <i>et al.</i> , “COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer,” <i>Nucleic Acids Res.</i> (2011) (Forbes)

<u>PETITIONER’S UPDATED EXHIBIT LIST</u>	
EX1036	Y. Kohara, “DNA probes on beads arrayed in a capillary, 'Bead-array', exhibited high hybridization performance,” Nucleic Acids Res. (2002) (<i>Kohara</i>)
EX1037	Infringement Claim Chart for U.S. Patent No. 11,408,033; EXO to Patent Owner’s FAC
EX1038	C. Vale <i>et al.</i> , “Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.” Cancer Treat Rev. (2012) (<i>Vale</i>)
EX1039	Wagle Supplementary Tables
EX1040- EX1069	Reserved
EX1070	S. Dawson, <i>et al.</i> , “Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer,” New England Journal of Medicine (2013) (<i>Dawson</i>)
EX1071- EX1077	Reserved
EX1078	Additional Excerpts from Application No. 14/810,337 (EX2004)
EX1079	Declaration of Alan J. Heinrich iso Motion for <i>Pro Hac Vice</i> Admission
EX1080 (New)	Transcript of the Proceedings (Conference Call between Parties & Board - 02.22.24)
EX1081	Petitioner's Oral Hearing Demonstratives
EX1082- EX1111	Reserved
EX1112	U.S. Publication No. 2022/0195530, issued to Diehn <i>et al.</i> , (<i>Diehn-530</i>)

<u>PETITIONER’S UPDATED EXHIBIT LIST</u>	
EX1113- EX1207	Reserved
EX1208	Exemplary chart of Personalis™ test practicing claim 1 of U.S. Patent No. 11,384,394
EX1209	Genome assembly NCB136 https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000001405.12/ (Furneux Depo EX1209)
EX1210	90% Chart (EX1210 from Furneaux Depo)
EX1211	U.S. Patent No. 11,456,058, issued to West <i>et al.</i>
EX1212	U.S. Patent No. 11,584,968, issued to West
EX1213	Pasaniuc, <i>et al.</i> , “Extremely low-coverage sequencing and imputation increases for genome-wide association studies”
EX1214	(Personalis) U.S. Patent No. 11,640,405 issued to Chandratillake
EX1215	Jain, <i>et al.</i> , “Single molecule pull-down for studying protein interactions” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654178/
EX1216	Amplicon NGS battle begin in earnest - Enseqlopedia https://enseqlopedia.com/2011/10/amplicon-ngs-battles-begin-in-earnest/
EX1217	Biocompare Editorial Article, “Maximize Your NGS with Sequence Capture”
EX1218	Heitzer, <i>et al.</i> , “Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing”
EX1219	Reserved
EX1220	[Redacted] Norton Deposition Transcript, Nov. 21, 2023

<u>PETITIONER’S UPDATED EXHIBIT LIST</u>	
EX1221	[Redacted] MacQuitty Depo Transcript, Dec. 1, 2023
EX1222	[Redacted] West Depo Transcript, Dec. 8, 2023
EX1223	Furneaux Depo Transcript, Dec. 12, 2023
EX1224	U.S. Patent No. 11,384,394 to Bartha <i>et al.</i>
EX1225	Declaration of John Quackenbush, Ph.D. iso Petitioner’s Reply

Dated: March 15, 2024

Respectfully submitted,

/Andrew E. Krause/

Andrew E. Krause, Reg. No. 76,276
Abigail Sellers, (Reg. 80,391)
Alan J. Heinrich (*pro hac vice*)
IRELL & MANELLA LLP
1800 Avenue of the Stars, Ste. 900
Los Angeles, CA 90067
(310) 203-7668
akrause@irell.com

Amir Naini, Reg. No. 45,770
NAINI P.C.
2632 Wilshire Blvd., Suite 268
Santa Monica, CA 90403
(310) 592-3030
amir@nainipc.com

Attorneys for Petitioner
Foresight Diagnostics Inc.

CERTIFICATE OF SERVICE

I hereby certify, pursuant to 37 C.F.R. section 42.6, that on March 15, 2024, a complete copy of the foregoing document **PETITIONER'S UPDATED EXHIBIT LIST** and **EX1081** (Petitioner's Oral Hearing Demonstratives) were served upon the following, by ELECTRONIC MAIL:

WEIL, GOTSHAL & MANGES LLP

Derek C. Walter, Reg. No. 74,656

Derek.walter@weil.com

Adrian Percer, Reg. No. 46,986

Adrian.percer@weil.com

Personalis.Foresight@weil.com

Nathanel Luman, Reg. No. 63,160

2nrl@knobbe.com

BoxPersonalis394@knobbe.com

/Susan M. Langworthy/

Susan M. Langworthy